Safety in oHCM Therapy: How and When to Transition Treatment?
Anjali Owens, MD
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Joseph Rossano, MD
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
Ahmad Masri, MD, MS
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
Pam R. Taub, MD, FACC, FASPC
The Patient-Clinician Connection in Managing CKD-aP
James Burton, DM, FRCP
Lucio Manenti, MD, PhD
CKD-aP or Something Else? Decoding the Diagnosis
Emilio Sanchez, MD, PhD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
Leonie Kraft, MD
Quantifying CKD-aP: Tools for Better Care
CKD-aP Treatment Tool Kit